Clinical

Therapeutic implications reported in relation to a unique dominant RPE65 mutation with autosomal dominant retinitis pigmentosa (adRP)

Researchers at the Institute of Genetics, TCD, Dublin and the Department of Ophthalmology, McGill University, Montreal have reported significant research results supporting replenishment of the… Read More »Therapeutic implications reported in relation to a unique dominant RPE65 mutation with autosomal dominant retinitis pigmentosa (adRP)

A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.

A team of clinical researchers based at Johns Hopkins Hospital, Baltimore, Maryland, has reported findings of equivalent efficacy and similar safety and immunogenicity profiles with… Read More »A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.

Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.

Clinical researchers at the NHS Foundation Trust, Sheffield, UK have found that real-world evidence on the effectiveness and safety of a fluocinolone acetonide (FAc) implant… Read More »Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.